Procept BioroboticsPRCT
PRCT
About: PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
Employees: 626
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
117% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 30
51% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 75
29% more call options, than puts
Call options by funds: $19.5M | Put options by funds: $15.1M
11% more funds holding
Funds holding: 246 [Q3] → 273 (+27) [Q4]
9% more capital invested
Capital invested by funds: $3.72B [Q3] → $4.05B (+$337M) [Q4]
3.36% more ownership
Funds ownership: 89.64% [Q3] → 93.0% (+3.36%) [Q4]
13% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 7 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$105
69%
upside
Avg. target
$109
74%
upside
High target
$112
80%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Nathan Treybeck 50% 1-year accuracy 2 / 4 met price target | 80%upside $112 | Overweight Reinstated | 3 Dec 2024 |
Morgan Stanley Patrick Wood 64% 1-year accuracy 7 / 11 met price target | 69%upside $105 | Overweight Initiated | 2 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference
SAN JOSE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2024 after market close on Tuesday, February 25, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Positive
Zacks Investment Research
1 month ago
PROCEPT BioRobotics (PRCT) Upgraded to Strong Buy: Here's What You Should Know
PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Business Wire
1 month ago
Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on PROCEPT BioRobotics (NASDAQ: PRCT)
NEW YORK--(BUSINESS WIRE)--Spruce Point Capital Management, LLC (“Spruce Point” or “we” or “us”), a New York-based investment management firm that focuses on forensic research and short-selling, today issued a detailed report entitled, “Pulling Back the Curtain on Procept,” that outlines why we believe and estimate that shares of PROCEPT BioRobotics (Nasdaq: PRCT) (“Procept” or the “Company”) face up to 30% – 60% potential long-term downside to approximately $29 - $54 per share and has market u.
Neutral
GlobeNewsWire
2 months ago
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time.
Positive
Seeking Alpha
2 months ago
Procept BioRobotics: Continued Growth Runway Ahead
PRCT's Q3 sales were up 66% YoY, and gross margins reached a record 63%. Management forecasts $223mm in sales this year, with a 64% top-line growth. The business model ensures recurring revenue and operating leverage.
Positive
Zacks Investment Research
3 months ago
Are You Looking for a Top Momentum Pick? Why PROCEPT BioRobotics Corporation (PRCT) is a Great Choice
Does PROCEPT BioRobotics Corporation (PRCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
GlobeNewsWire
3 months ago
PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $175 million. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of the Company's common stock at the public offering price, less underwriting discounts and commissions. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The offering is expected to close on or about October 31, 2024, subject to customary closing conditions.
Positive
Zacks Investment Research
3 months ago
All You Need to Know About PROCEPT BioRobotics (PRCT) Rating Upgrade to Strong Buy
PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Investors Business Daily
3 months ago
Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook
Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates.
Neutral
GlobeNewsWire
3 months ago
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of the Company's common stock. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Charts implemented using Lightweight Charts™